Diseases
Attention-Deficit Hyperactivity Disorder (ADHD)
Competitor Analysis
| Publication Date | March 2009 |
| Publisher | La Merie |
| Product Type | Report |
| Pages | 24 |
| ISBN Number | not applicable |
| Product Code | LME00079 |
Price
approximately: $273 | €201
pdf immediate delivery
Order above formats by FAX
Summary
Product description
The present Competitive Intelligence Report about Attention-Deficit Hyperactivity Disoder (ADHD) provides a competitor evaluation in the field of approved and investigational drugs for treatment of ADHD as of March 2009.
Attention-deficit hyperactivity disorder (ADHD) is a common and highly heritable neurodevelopmental psychiatric disease. It is also an indication for commercially successful drugs. The major ADHD drugs posted 2008 sales of US$ 3.9 bln. The current generation of ADHD treatments are mostly CNS stimulants. Although the major classes such as amphetamine/lisdexamfetamine, methylphenidate and dexmethylphenidate have lost patent protection for the substance, the use of extended release or topical drug delivery formulations have maintained a rich source of revenues for major players J&J, Shire, Eli Lilly and Novartis. As many parents are concerned about the use of CNS stimulants for treatment of their kids due to their addictive properties, research is focused on new non-stimulant drug targets. Most of them are in clinical phase I and II evaluation and include reuptake inhibitors, glutaminerigic substances, histamine antagonists and nicotinic receptor agonists
The report includes a compilation of marketed products and their sales in 2008 and current active projects in research and development of ADHD. In addition, the report lists company-specific product portfolios and R&D pipelines in ADHD.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Contents
- Index
- Attention-Deficit Hyperactivity Disorder (ADHD) pipeline
- About La Merie
- Corporate R&D Pipelines in ADHD
- Abbott
- Addrenex Pharmaceuticals
- Alseres Pharmaceuticals
- Auriga Laboratories
- Cortex Pharmaceuticals
- Curidium
- Eli Lilly
- GlaxoSmithKline (GSK)
- IMPAX
- Johnson & Johnson (J&J)
- KemPharma
- Merck & Co.
- NeuroSearch
- Novartis
- Pfizer
- Pierre Fabre
- Schering-Plough
- Shire
- Shionogi
- Supernus Pharmaceuticals
- Targacept
- Teva Pharmaceutical Industries
- UCB
- Watson Pharmaceuticals
- Xytis
